Nordicus Partners Corp (NORD): M&A transaction — Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market

Nordicus Partners Corp

Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.
Consideration valued at $38M in an all-stock transaction; closed May 13, 2024.
Nordicus CEO Henrik Rouf and Director Henrik Keller join Orocidin's board of directors.
Orocidin is a clinical-stage biopharma developing QR-01 for periodontitis; global market estimated >$1.3B by 2029.

item 1.01 item 2.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Nordicus Partners Corp completed an acquisition involving certain shareholders of Orocidin A/S (closed 2024-05-13).

Action: acquisition
Counterparty: certain shareholders of Orocidin A/S
Closing: 2024-05-13

Exact text from the filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nordicus Partners Corp entered into Stock Purchase and Sale Agreement with certain shareholders of Orocidin A/S (effective 2024-05-13).

Action: entry
Agreement: asset purchase
Counterparty: certain shareholders of Orocidin A/S
Effective: 2024-05-13

Exact text from the filing

On May 13, 2024, Nordicus Partners Corporation (the “Company”) and certain shareholders (the “Sellers”) of Orocidin A/S, a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock.

View on SEC.gov

4 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Nordicus Partners Corp filing history →

Source: SEC EDGAR

accession 0001493152-24-020152

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.